Marek Ziobro

Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma

David F. McDermott, Jae‐Lyun Lee, Marek Ziobro et al. · Journal of Clinical Oncology · 2021 · 277 citations · Full text

First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Results from KEYNOTE-427 cohort B.

David F. McDermott, Jae‐Lyun Lee, Marek Ziobro et al. · Journal of Clinical Oncology · 2019 · 54 citations

Advanced Ccrcc, Immunology, Pharmacotherapy +19

KEYNOTE-427 cohort B: First-line pembrolizumab (pembro) monotherapy for advanced non‒clear cell renal cell carcinoma (NCC-RCC).

Jae‐Lyun Lee, Marek Ziobro, Rustem Gafanov et al. · Journal of Clinical Oncology · 2019 · 29 citations

Pd-1 Inhibitors, Pathology, Pharmacotherapy +19

Microvessel Density and Status of p53 Protein as Potential Prognostic Factors for Adjuvant Anthracycline Chemotherapy in Retrospective Analysis of Early Breast Cancer Patients Group

Beata Biesaga, Joanna Niemiec, Marek Ziobro · Pathology & Oncology Research · 2012 · 21 citations · Full text

Breast Oncology, Microvessel Density, Medicine +12

BRAF and MEK inhibitors rechallenge as effective treatment for patients with metastatic melanoma

Bożena Cybulska-Stopa, Paweł Rogala, Anna M. Czarnecka et al. · Melanoma Research · 2020 · 21 citations